DEERFIELD, Ill. & SAN DIEGO--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the United States Food and Drug Administration ...

After a gradual adjustment period, the Hyqvia dose is 300-600 mg/kg, every 3 to 4 weeks. The dose is adjusted individually based on body weight, medical history, symptom severity, and treatment ...

OSAKA, Japan & CAMBRIDGE, Mass., January 29, 2024--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved HYQVIA ® [Immune Globulin Infusion 10% (Human) ...

In 2014, Baxter got HyQvia over the FDA finish line for patients with primary immunodeficiency (PI). Eight years and three companies later, Takeda is finding more uses for the subcutaneous treatment.

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced full results from the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial investigating HYQVIA® [Immune Globulin ...

OSAKA, Japan & CAMBRIDGE, Mass., June 18, 2024--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Takeda Pharmaceutical’s Hyqvia, coformulated with Halozyme's Enhanze drug delivery ...

HYQVIA ® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], the Only Once-a-Month – Every Three or Four Weeks – Subcutaneous Immunoglobulin (ScIG), is Now Approved for People ...

HyHub and HyHub Duo Reduce the Number of Steps Required to Prepare HYQVIA 1 First Devices Customized for a Plasma-Derived Therapy in Takeda’s Broad and Differentiated Portfolio Reflect Company’s ...

This proposed extension of indication for HYQVIA is based on data from the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial, which investigated HYQVIA as maintenance therapy in adult patients with CIDP.